Business context and reporting period
Filing identity: The provided filing is Eyenovia, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022 (ticker EYEN), not Hyperion DeFi, Inc. The company is a clinical-stage ophthalmic therapeutics developer using its Optejet microdose delivery platform.
Its product pipeline includes MicroPine for progressive myopia, MicroLine for presbyopia, and Mydcombi for pupil dilation. The company had no recurring revenue and remained pre-profitability.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | $0 | $2.0 million |
| Gross profit | $0 | $1.2 million |
| Research and development expense | $3.7 million | $4.3 million |
| General and administrative expense | $3.5 million | $2.2 million |
| Operating loss | $7.2 million | $5.4 million |
| Net loss | $7.3 million | $5.4 million |
| Basic and diluted loss per share | $0.24 | $0.21 |
| Cash and cash equivalents | $26.7 million | $19.5 million at Dec. 31, 2021 |
| Restricted cash | $7.9 million | $7.9 million at Dec. 31, 2021 |
| Working capital | $20.0 million | $10.8 million at Dec. 31, 2021 |
| Notes payable, gross | $8.1 million | $7.5 million at Dec. 31, 2021 |
Operating cash use was $8.2 million, versus $4.6 million a year earlier. Investing cash use was $0.2 million; financing provided $15.6 million, mainly from a registered direct offering and the at-the-market program. Cash, cash equivalents and restricted cash totaled $34.6 million at quarter-end. The balance sheet reported total liabilities of $10.4 million and stockholders’ equity of $29.8 million.
Material changes versus the prior comparable period
- Revenue fell from $2.0 million to zero. The prior-year amount reflected recognition of half of an Arctic Vision upfront license payment; no Arctic Vision or Senju license payments were earned or recognized in Q1 2022.
- Net loss increased by approximately $2.0 million. R&D expense declined 14% as 2021 included product manufacturing and testing that did not recur, while G&A expense rose 59%, largely due to professional fees, hiring, compensation, stock-based compensation, and insurance costs.
- Operating cash use increased by approximately $3.6 million year over year.
- The company raised approximately $15.0 million gross in a March registered direct offering of common stock and warrants and received approximately $0.9 million net from ATM sales. Common shares outstanding were 31.7 million at March 31, compared with 28.4 million at year-end.
Outlook, risks, contingencies, and unusual items
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after issuance of the financial statements. Continued operations depend on additional capital or licensing/business-development transactions; without funding, the company may curtail R&D and reduce costs.
- Pipeline outlook: Management expected top-line results from the VISION-2 Phase III presbyopia study in mid-2022. Following an FDA complete response letter for Mydcombi, the company expected to provide additional nonclinical device information and resubmit its NDA in Q3 2022. The filing gives no financial guidance.
- Clinical and regulatory risk: MicroPine trial enrollment had been delayed by COVID-related supplier and inventory issues. Product candidates require FDA review as drug-device combination products, and approval and commercialization remain uncertain.
- Debt and restricted funds: $7.875 million was pledged as collateral under the Silicon Valley Bank loan. On May 6, 2022, the loan repayment term was amended to 24 consecutive months, with the first payment extended to June 1, 2023.
- Other commitments: Management disclosed next-12-month commitments including $2.6 million to settle accounts payable and accrued expenses, $0.5 million in operating lease commitments, $1.5 million of potential executive severance, and $8.1 million of note payments. Executive severance is contingent on qualifying termination and release conditions.
- Subsequent event: After quarter-end, 1,870,130 pre-funded warrants were exercised for $18,701 gross proceeds. The filing reports no material legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the filing is for Eyenovia, Inc., not the company named in the request metadata.
- Assess the going-concern warning, expected cash burn, and the timing and availability of additional financing.
- Track VISION-2 results and the anticipated Mydcombi NDA resubmission, including FDA review outcomes.
- Review dilution from the March offering, outstanding warrants and options, and any further ATM issuance.
- Check the SVB loan amendment, collateral restrictions, and the timing of debt repayments.